MedDataX Logo

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery

NCT ID: NCT01535222

Last Updated: 2012-07-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-11-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate that periprocedural infusion of escalating doses of MDCO-2010 is safe and tolerated in patients undergoing elective CABG surgery, to characterize the single dose pharmacokinetics of MDCO-2010, to investigate the effect of MDCO-2010 on pharmacodynamics (biomarkers of fibrinolysis and coagulation parameters), and to investigate the effect on exploratory clinical endpoints of bleeding, transfusion requirements and reexploration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This protocol describes a study of the investigational drug MDCO-2010 as a haemostasis modulator in patients undergoing elective Coronary Artery Bypass Graft (CABG) surgery involving a cardiopulmonary bypass (CPB).

Perioperative bleeding is a serious complication that adversely affects the morbidity and mortality of cardiac surgery. To alleviate this complication, prophylactic antifibrinolytic therapies are now widely accepted as a strategy to inhibit excessive fibrinolysis.

MDCO-2010, a synthetic small molecule, is a direct inhibitor of plasmin and plasma kallikrein. Both of these have been implicated with impaired haemostasis. In addition, potent inhibition of coagulation factors Xa, XIa and activated Protein C has been demonstrated. Thus, MDCO-2010 has the potential to mitigate excessive fibrinolysis and thrombin generation during cardiac surgery involving a cardiopulmonary bypass. In particular the latter is supposed to provide additional benefits beyond reducing transfusion requirements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Bypass Graft Cardiopulmonary Bypass

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

cardiac surgery coronary artery bypass graft cardiopulmonary bypass haemostasis modulator blood loss direct inhibitor of plasmin and plasma kallikrein CABG CPB

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

3 patients: loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg

Group Type EXPERIMENTAL

MDCO-2010

Intervention Type DRUG

MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery

Cohort 2

3 pts: loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg

Group Type EXPERIMENTAL

MDCO-2010

Intervention Type DRUG

MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery

Cohort 3

6 patients: loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg

Group Type EXPERIMENTAL

MDCO-2010

Intervention Type DRUG

MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery

Cohort 4

6 patients: loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg

Group Type EXPERIMENTAL

MDCO-2010

Intervention Type DRUG

MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery

Cohort 5

6 patients: loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg

Group Type EXPERIMENTAL

MDCO-2010

Intervention Type DRUG

MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery

Placebo

8 patients: commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Commercially available NaCl

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MDCO-2010

MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery

Intervention Type DRUG

Placebo

Commercially available NaCl

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CU-2010

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men, aged 18 to 80 years or
* Post-menopausal women, aged up to 80 years. Postmenopausal status defined as ≥ 1 year since last menstruation in women with no medical history of hysterectomy or women with a medical history of bilateral oophorectomy
* Planned elective, isolated primary CABG surgery with more than 1 graft, including the use of cardiopulmonary bypass
* Written informed consent prior to any study-related procedure not part of normal medical care

Exclusion Criteria

* Planned concomitant surgery including atrial septal defect (ASD) repair, valve replacement, carotid endarterectomy, aortic surgery, any combined procedure or any repeat sternotomy
* Planned Off-pump CABG
* Body weight \< 55 kg or \> 110 kg
* Planned hypothermia \< 28°C
* Major surgical procedures within 30 days of entry
* Placement of drug-eluting stent (DES) within 12 months or of bare-metal stent (BMS) within 6 weeks of entry in a vessel which is not intended to be grafted
* Ejection fraction \< 35%
* Preoperative coagulation abnormalities

* Platelet count \< 100,000/cubic mm, or
* INR \> 1.5 or Quick \< 40%, or
* activated partial thromboplastin time (aPTT) \> 1.5 x upper limit of normal (ULN)
* Preoperative Hb \< 11 g/dL for male patients or \< 10 g/dL for female patients
* Patient refusal to receive donor blood products if necessary
* Administration of thienopyridines within 5 days prior to surgery Administration of warfarin within 5 days prior to surgery
* Administration of tirofiban or eptifibatide within 24 hours or administration of abciximab within 5 days prior to surgery
* Administration of fondaparinux within 24 hours prior to surgery
* Creatinine clearance (calculated using Cockroft-Gault equation) \< 60 mL/min
* Planned intraoperative use of tranexamic acid or of ε-aminocaproic acid
* History of stroke or transient ischemic attack within 3 months prior to entry
* Known heparin-induced thrombocytopenia
* Known history of thrombophilia, eg, deep vein thrombosis (DVT) with pulmonary embolism
* Active liver disease
* Any condition requiring chronic immunosuppressive medication
* Receipt of an investigational drug or device 30 days prior to entry
* Any other condition which, in the opinion of the investigator, would prevent a patient's participation in the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Medicines Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lars Englberger, PD Dr. Med.

Role: PRINCIPAL_INVESTIGATOR

Insel Gruppe AG, University Hospital Bern

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TMC-CU-10-01

Identifier Type: -

Identifier Source: org_study_id